FDA Gives Green Signal To Inventiva's Mid-Stage Lanifibranor Study In NASH Patients


The FDA has completed a safety review of Inventiva SA's IVA IND application and signed off Phase 2 combination trial with its lead drug candidate, lanifibranor.

  • The planned Phase 2 trial, LEGEND3, has been designed as a proof-of-concept trial to assess the safety and efficacy of lanifibranor combined with empagliflozin for non-cirrhotic NASH and Type 2 Diabetes (T2D). 
  • LEGEND is expected to recruit a total of 63 non-cirrhotic non-alcoholic steatohepatitis (NASH) patients with T2D.
  • Related: Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor.
  • The trial's primary efficacy endpoint is a change in Hemoglobin A1c (HbA1c) at the end of the 24-week treatment compared to baseline. Secondary endpoints include changes in liver enzymes, glycaemic and lipids parameters, inflammatory markers, and body fat composition. 
  • The trial will be initiated in 1H of 2022, and top line results are expected for 2H of 2023.
  • Price Action: IVA shares closed 3.53% lower at $10.94 on Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!